Science that is transforming lives and enabling the future
Entegris is proud to announce a new relationship with Farrar Scientific, by Trane Technologies – a global climate innovator. Farrar offers best-in-class operating systems for ultra-cold temperature storage and controlled rate freeze/thaw chambers for pharmaceutical, biotech, and biorepository applications. Entegris offers the best-in-class Aramus™ bag for robust cold storage and transport. Collaborating with Farrar enables Entegris to offer a combined solution that accelerates the freeze/thaw process. Powered by Trane Technologies, Farrar’s solutions fill an unmet need for large pharmaceutical and biopharmaceutical customers requiring flexible, modular, and efficient ultra-low temperature freeze/thaw processing, as well as -80°C (-112°F) bulk storage reach-ins and -70°C (-94°F) pallet chambers. Farrar’s offerings and monitoring services, which include predictive analytics, provide an alternative to large-scale freezer farms or capital-intensive cold rooms used in the manufacturing of drugs, vaccines, and other biological products. Forced air convection cooling in Farrar’s controlled rate chamber greatly reduces +40˚ to -80˚C (+104° to -112°F) freeze/thaw times from days or weeks to hours, optimizing manufacturing efficiency and improving characteristics such as uniformity and repeatability versus competing technologies."This collaboration is a win-win for the industry,” said Holly Paeper, president, Trane Technologies Life Science Solutions. “Farrar and Entegris solutions jointly represent a step forward in reliability, simplicity, and affordability for end-to-end bioprocessing. We’re excited to discover how we can jointly advance precision temperature technology that helps protect quality and optimizes manufacturing.” Entegris will showcase Farrar’s controlled rate chamber in our new Life Sciences Technology Center in Billerica, MA, which offers life sciences customers the opportunity to leverage our expertise in cold-chain challenges to reduce costs, increase speed to market, and optimize processes. This premier facility brings Entegris’ tools and technologies together in one place, where customers can test equipment for freeze/thaw processes to determine which products best fit their needs. As part of our solutions for manufacturing challenges, we now offer Aramus shaped 2D single-use bags with custom shapes, sizes, and assembly configurations for customers’ space and function requirements. They are resistant to extreme cold temperatures and withstand gamma sterilization, which makes them a preferred solution for freezing, transporting, storing, and thawing drug substances, like COVID-19 vaccines, cell therapies, and gene therapies. “Our new technology center enables our customers to really understand the whole freezing process and optimize it before setting up a new lab of their own,” said John Lynch, vice president, Entegris. “Together with Farrar we are able to provide novel and high-value options for bulk drug freezing.”
Entegris is proud to announce a new relationship with HOF Sonderanlagenbau GmbH, an international provider of freeze/thaw equipment and special solutions for the pharmaceutical and biotechnology sectors. Entegris offers the best-in-class Aramus™ bag for robust cold storage and transport. Collaborating with HOF enables Entegris to offer a combined solution for our customers that accelerate the freeze/thaw process and help showcase our new Life Sciences Technology Center, built to offer customers the opportunity to leverage our cold-chain supply expertise to optimize processes, reduce costs, and increase speed to market.
Summer is the perfect season to enjoy the great outdoors with friends and family. Unless, of course, the air is filled with smoke and ash. The color-coded air quality readings too often go beyond the red danger zone into purple, with an Air Quality Index (AQI) of over 200 parts per million (ppm) of particulate contamination. This particulate count is far above what is safe even for healthy adults. In many parts of the western U.S. and beyond, purple air has become far too familiar.
The explosion of data generation has been accompanied by a corresponding explosion of memory storage technology options. The array of acronyms is astounding—NAND, DRAM, SRAM, MRAM, PCRAM—and finding the right option can be complicated. For applications that need nonvolatile memory with high switching speed and fast data access, storage class memory (SCM) can be a perfect fit.
Whether it is a deliberate strategy or serendipity, the innovations that shape our lives are the result of skilled people put into the right environment to create something new. Innovation is not an exact science, but persistence and some good luck have yielded all the amazing tools and technology we rely upon.
Entegris recently participated at SEMICON West in San Francisco, CA, July 12 – 14. After three years without a major onsite presence, the team was eager to be back in person and engage face-to-face with key customers and suppliers.
Like Benjamin Franklin once stated, “An ounce of prevention is worth a pound of cure.” This could be said for mitigating risk to storage of your biologics too. Even the slightest temperature change from a freezer door being opened and closed numerous times to setting alarms off while searching for product hidden inside can compromise drug product. Losing time and money over product can be prevented. Here are some tips to keep your biologics viable in both long- and short-term freezer storage.
Protecting your product throughout the freeze/thaw process can be a delicate task. Freeze too slowly, your proteins may aggregate and degrade. Thaw in a water bath, you might encounter contamination. Most commonly, cryo-concentration, where your protein is not evenly distributed throughout your frozen container, poses a risk to critical product quality attributes. There are countless ways improper freeze/thaw processes can ruin sensitive therapeutics and cell and gene therapies, but the proper tools can help you reduce cryo-concentration and bioburden while achieving the best return on investment and optimization of your process.
The great resignation, retirement, and an increase in remote work have caused instability across every industry, this is especially true in cell and gene therapy. Getting critical therapies to market has been increasingly difficult due to the high demand for team members with experience in this area, so what can companies do to help combat this?
In February 2022, we entered the Lunar Year of the Tiger. Fittingly, semiconductor demand is as ferocious as the tiger and shows no signs of easing up soon. To meet this demand, the industry must be as efficient as possible.
As a world-class supplier of advanced materials and process solutions for the semiconductor space, we understand the complexity and challenges of quality by design with respect to bulk drug cold chain manufacturing. Costly failures can be devastating and, in many cases, can be avoided by partnering with the correct single-use solutions provider to help optimize critical processes. When looking for solutions to protect your therapeutics during bulk drug cold chain, keep the following in mind:
Meet Regulatory Requirements to Ensure Patient Safety Developing and validating a robust freeze/thaw process while meeting regulatory guidelines is a multifaceted challenge. The demand for cold chain processes and operations for biopharma products is increasing due to scaling of complex therapeutics, a challenging global supply chain, and growing shipping complexities. Ensuring compliance throughout the product journey is integral to mitigating risk for product loss and contamination.